SCHEMBL23946141

SCHEMBL23946141

CNc1cn(-c2ccc(C(=O)OC)cc2)nc1C(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
HTT P42858 2/20 0.40
MAPT P10636 4/20 0.39
KDM4E B2RXH2 3/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 2/20 0.38
HPGD P15428 2/20 0.38
POLB P06746 2/20 0.38
MEN1 O00255 1/20 0.38
HSP90AA1 P07900 1/20 0.38
KMT2A Q03164 1/20 0.38
CA1 P00915 3/20 0.37
CA2 P00918 3/20 0.37
CA12 O43570 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21070025 0.83 HSD17B10 (0.42) ALDH1A1HTTMAPTKDM4ENPC1
SCHEMBL21069438 0.83 PTGS1 (0.42) ALDH1A1HTTMAPTKDM4ENPC1
SCHEMBL21997183 0.83 LCK (0.37) ALDH1A1HTTMAPTKDM4ENPC1
SCHEMBL21997660 0.79 SMN1; SMN2 (0.44) ALDH1A1HTTMAPTKDM4ENPC1
SCHEMBL21069448 0.76 ALDH1A1 (0.35) ALDH1A1HTTMAPTKDM4ENPC1
SCHEMBL21070628 0.76 ALDH1A1 (0.41) ALDH1A1MAPTKDM4ENPC1TP53
SCHEMBL31364248 0.70 MEN1 (0.49) ALDH1A1HTTMAPTTDP1HPGD
SCHEMBL6500092 0.69 KDM4E (0.47) ALDH1A1HTTMAPTKDM4ENPC1
SCHEMBL21069305 0.68 KCNJ1 (0.44) ALDH1A1HTTMAPTNPC1RAB9A
SCHEMBL3666878 0.68 FGFR1 (0.52) ALDH1A1HTTMAPTKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 US disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885HTT 2464/4885MAPT 2459/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885HTT 2464/4885MAPT 2459/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885HTT 2464/4885MAPT 2459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.